1. Home
  2. WYNN vs PRAX Comparison

WYNN vs PRAX Comparison

Compare WYNN & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wynn Resorts Limited

WYNN

Wynn Resorts Limited

HOLD

Current Price

$81.28

Market Cap

10.1B

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$281.89

Market Cap

8.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WYNN
PRAX
Founded
2002
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1B
8.3B
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
WYNN
PRAX
Price
$81.28
$281.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
15
Target Price
$142.73
★ $572.13
AVG Volume (30 Days)
★ 1.8M
356.7K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
★ 0.96%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 2.36
N/A
Revenue
★ $6,717,660,000.00
N/A
Revenue This Year
$6.49
N/A
Revenue Next Year
$4.58
$7,758.26
P/E Ratio
$33.98
★ N/A
Revenue Growth
★ 10.67
N/A
52 Week Low
$77.06
$50.23
52 Week High
$134.72
$392.70

Technical Indicators

Market Signals
Indicator
WYNN
PRAX
Relative Strength Index (RSI) 27.48 26.03
Support Level N/A $269.44
Resistance Level $107.47 $331.21
Average True Range (ATR) 2.38 15.24
MACD -0.40 -5.85
Stochastic Oscillator 27.34 6.71

Price Performance

Historical Comparison
WYNN
PRAX

About WYNN Wynn Resorts Limited

Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming rooms and attractions in Macao over the next few years, including a new 432-suite tower adjacent to its Palace resort opening in 2029. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company received 49% and 51% of its 2025 prepandemic EBITDA from Macao and the US, respectively.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: